<DOC>
	<DOCNO>NCT03105596</DOCNO>
	<brief_summary>This prospective phase II clinical trial observe efficacy safety Chidamide combine DICE ( Dexamethasone , Ifosfamide , Cisplatin Etoposide ) patient relapsed refractory B-cell Non-Hodgkin 's Lymphoma ( NHL ) .</brief_summary>
	<brief_title>Chidamide Plus DICE Regimen Patients With Relapse Refractory B-cell Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description>Chidamide，a novel histone deacetylase inhibitor approve treatment relapse refractory peripheral T-cell lymphoma China . The aim study observe efficacy safety Chidamide combine DICE patient relapse refractory B-cell Non-Hodgkin 's Lymphoma ( NHL ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>1 . Diagnosed Bcell NonHodgkin 's Lymphoma ( NHL ) accord `` 2008 WHO classification tumor haematopoietic lymphoid tissue '' , include Diffuse Large BCell Lymphoma , Follicular Lymphoma , Mantle Cell Lymphoma , Marginal Zone Lymphoma , transform indolent lymphoma , subtypes investigator consider appropriate enrol ; 2 . Patients must receive least one systemic treatment ( include chemotherapy ) , achieve remission relapse remission ; 3 . At least one measurable lesion ; 4 . Age1865 year , male female ; ECOG performance status 01 ; 5 . Without bone marrow involvement . Blood routine test : absolute neutrophil count ≥1.5 × 109/L , platelet ≥100 × 109/L , Hb ≥ 90g/L ; . 6 . Life expectancy le 3 month ; 7 . Not received chemotherapy , target medicine stem cell transplantation 4 week enrollment ; 8 . Patients sign Informed Consent Form . 1 . Women pregnancy lactation , fertile woman unwilling take contraceptive measure . 2 . QTc elongation clinical significance ( male˃ 450ms , female˃ 470ms ) , ventricular tachycardia , atrial fibrillation , cardiac conducting blockage , myocardial infarction within 1 year , congestive heart failure , symptomatic coronary heart disease require treatment ; 3. pericardial effusion ≥10mm sum echofree space echocardiography ; 4 . Patients undergone organ transplantation ; 5 . Patients receive symptomatic treatment bone marrow toxicity within 7 day prior enrollment . 6 . Patients active hemorrhage . 7 . Patients history thrombosis , embolism , cerebral hemorrhage , cerebral infarction . 8 . Patients active infection , continuous fever within 14 day prior enrollment . 9 . Patients active infection HBV , HCV HIV ; 10 . Had major organ surgery within 6 week prior enrollment . 11 . Impaired liver function ( Total bilirubin ˃ 1.5 time normal maximum , ALT/AST˃ 2.5 time normal maximum , patient infiltrative liver disease ALT/AST ˃ 5 time normal maximum ) , impaired renal function ( serum creatinin˃ 1.5 time normal maximum ) . 12 . Patients mental disorder ability consent . 13 . Patients drug abuse , long term alcoholism may impact result trial . 14 . Patients central nervous system involvement ; 15 . Nonappropriate patient trial accord judgment investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>